Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619585 | 1.00 | DPP4 (0.47) | DPP4SLC7A5ALDH1A1LMNAMMP1 | |
| SCHEMBL19883548 | 0.87 | CA12 (0.42) | DPP4SLC7A5LMNAMMP1MMP2 | |
| SCHEMBL8613006 | 0.82 | DPP4 (0.43) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL19981940 | 0.82 | DPP4 (0.44) | DPP4SLC7A5ALDH1A1LMNADPP8 | |
| SCHEMBL8613010 | 0.82 | DPP4 (0.43) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL8615960 | 0.80 | DPP4 (0.42) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL8615969 | 0.80 | DPP4 (0.42) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3948078 | 0.80 | DPP4 (0.42) | DPP4ALDH1A1LMNAMMP1MMP2 | |
| SCHEMBL5438409 | 0.80 | DPP4 (0.42) | DPP4ALDH1A1LMNAMMP1MMP2 | |
| SCHEMBL23368288 | 0.79 | DPP4 (0.42) | DPP4SLC7A5DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| US-20220079924-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ORIC PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210122730-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ORIC PHARMACEUTICALS, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20210122730-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ORIC PHARMACEUTICALS, INC. | 2021-04-29 | — | — | US | disclosed |
| EP-3609872-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Oric Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018191283-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ORIC PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
| US-8829024-B2 | Combination steroid and glucocorticoid receptor antagonist therapy | CORCEPT THERAPEUTICS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8557839-B2 | Fused ring azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130012486-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | Corcept Therapeutics, Inc. (019904) (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120225856-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012094618-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | CORCEPT THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20110166110-A1 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators | CORCEPT THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7928237-B2 | Fused ring azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1735308-B1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070281928-A1 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators | CORCEPT THERAPEUTICS INCORPORATED | 2007-12-06 | — | — | US | disclosed |
| EP-1735308-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005087769-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166110-A1 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators | NR3C1, NR3C2, NR5A2 | DPP4 2714/4885SLC7A5 4425/4885ALDH1A1 4094/4885 |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | DPP4 3504/4885SLC7A5 1653/4885ALDH1A1 637/4885 |
| US-20120225856-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A2 | DPP4 2714/4885SLC7A5 4425/4885ALDH1A1 4094/4885 |
| US-20210122730-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | DPP4 2883/4885SLC7A5 3801/4885ALDH1A1 3599/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | DPP4 3757/4885SLC7A5 1983/4885ALDH1A1 977/4885 |
| US-20130012486-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | NR3C1, NR3C2, NR5A1 | DPP4 2088/4885SLC7A5 4725/4885ALDH1A1 3786/4885 |
| US-20220079924-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | DPP4 2883/4885SLC7A5 3801/4885ALDH1A1 3599/4885 |
| US-20070281928-A1 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators | NR3C1, NR3C2, NR5A2 | DPP4 2714/4885SLC7A5 4425/4885ALDH1A1 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.